Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Will believe it when I see it. Not holding my breath.
Not really. It's the perfect stock to knock down. Management stays silent. Never buys shares. Investor relations does not respond to emails.
Perfect stock to continue to knock down.
Do you really believe management will surprise one of these days with a PR?
The good thing is the Magistrate's decision came like a day or a few days before GSK v. Teva's decision.
here's the article:
Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases
9:14 am ET October 5, 2021 (Benzinga) Print
Image by Gerd Altmann from Pixabay
How well we think, feel and act rests in the hands of trillions of tiny connectors in our minds.
Synapses play an integral role in how we function; they are tiny gaps that allow neurons to communicate with each other. When they aren’t working correctly or are damaged, it can lead to less connectivity, a weaker nervous system, and impaired cognition in the brain. It’s no surprise that loss of these synapses can lead to major neurological diseases like Alzheimer’s disease and dementia that interfere with a person’s ability to operate independently.
Nearly 1 in 6 people around the world suffer from neurological diseases each year, and unfortunately, there are limited treatment options are available. Thanks to the clinical-stage biotech company Synaptogenix (NASDAQ: SNPX), a restorative and novel form of therapy for these degenerative diseases may be on the horizon soon.
Getting the Brain Back On Track
Its product, Bryostatin-1, activates the protein kinase C-epsilon (PKC-epsilon), which affects the cognitive function of the patient as it promotes both neuronal health and synaptic regeneration. Unlike similar products made by Athira Pharma (NASDAQ: ATHA) and Cassava Sciences (NASDAQ: SAVA), Synaptogenix’s product directly affects the PKC-epsilon - synaptic growth pathways, showing improvement. Not only has the drug slowed cognitive decline in those with Alzheimer’s disease, it has actually improved cognitive function past baseline with the effect showing persistence after 1 month of dosing.
In its Phase 2 pilot for Alzheimer’s disease, Bryostatin-1 has also reported no safety issues and has been administered safely in over 1,600 patients. Aside from Alzheimer’s disease, the company is also looking at indications for other diseases and disorders like Fragile X syndrome, autism, multiple sclerosis, Parkinson’s disease, traumatic brain injury and stroke.
A Brighter Future Ahead
Valued at $30 million and led by a management team that has over 30 years in the field of neurodevelopmental disorders and developing novel drugs, Synaptogenix has received over $200 million of funding from Blanchette Rockefeller Neurosciences Institute and the National Institutes of Health (NIH) for further studies. In addition, it has numerous well-known partnerships, including the NIH, National Cancer Institute and National Institute on Aging.
Recently, Synaptogenix has made news by signing a memorandum of understanding with Nemours A.I. DuPont Hospital for Children to initiate trials using Bryostatin to treat Fragile X syndrome, announcing positive results from its Alzheimer’s trial, and acquiring a regenerative patent award with the U.S. Patent and Trademark Office. These patents could apply to treating degeneration of brain wiring in other neurological disorders such as Multiple Sclerosis, Fragile X mental retardation, Parkinson's disease, and cerebrovascular dementia.
Synaptogenix is in the business of rebuilding connections and restoring lives — one synapse at a time.
AMRN trading---I watch Level 2 like a hawk. It is comical and pretty much habitual what goes on.
Our stock gets smashed at the open every day then typically closes with strong volume / large bids at the end of the day. Maybe they are taking out stop losses or trying to scare retail into selling.....
https://www.griproom.com/fun/why-your-stock-is-always-red
but the same pattern occurs every day. it is comical
perhaps but had you told me a year ago we would still be at $5 in Oct. 2021 I would not have believed you.
The stock hit $9 and change upon European approval news.....why wasn't the company sold for $15 then......?????
We had JT's botched announcement he was retiring in August that came sometime in April.....SMH I say botched because look at the share price since......what was he doing those remaining months.....making coffee and surfing the internet....??
There's a reason why many biotech investors sell after the ADCOM vote/news.....if not right before
It's mind boggling and frustrating. Warren Buffett spoke about how bad management can ruin a company at his last shareholder meeting.
Wow. So the Wall Street analysts missed this...? They must not be factoring this in.
Thanks! I was going to pick up more shares but may wait a few days to see the price action.
Anyone surprised we are down today post the positive presentation from Dr. Alkon?
Though there would have been more excitement.
Got it. Whoever is doing it must be clued in on when news if any will come out.
Whoever is doing it is pretty certain nothing will move the stock so writing the option contracts as you mentioned is printing money and they are able to "control the stock."
Someone is "in the know" here.
$5 ping. What's with the constant holding us at $5. Seems that is support for the stock. Someone or some entity does not want it to fall below that price....We seem to always bounce off of it.
Anyone understand what's going on here....?
How do you figure that? Because Merck now has a covid play?
Someone should send the link to the Merck study to Dr. Corral on twitter and say good thing they waited for a conference to release groundbreaking results......LOL
You can't make this stuff up.
The power of a Big Pharma. Merck already met with the FDA.
Unfortunately Dr. Corral is more concerned about the attention he is getting and not releasing topline results.
I agree with P-Dude's assessment of P-2. Don't get your hopes up.
Thankfully we are a CVD stock.
Merck was able to rise to the occasion. The vaccine stocks will now likely take a hit / sell off.
I hope you're right.
Got it, thanks. Very helpful!
Do you all think we will hit $20 before results are released next year?
I was trying to recall the market cap of Neurotrope before results were released but I can't recall it having a huge run up prior to the release of results....
Will this time be different if so why?
As Q4 approaches, will this be a Q4/holiday to remember or more of the same....$5 to $5.50?
If it's more of the same, will have to rethink sticking around in 2022.
LBL any insight here....?
Our stock is stuck in the mud between $5 and $6. It is comical and sad. Let me be more accurate stuck between $5 and $5.50
https://www.griproom.com/fun/why-your-stock-is-always-red
https://www.griproom.com/fun/10-signs-your-stock-is-being-manipulated
I'm not banking on Dr. Corral who is enjoying the attention that is coming with this covid / fish oil study......
He could release the results if he wanted to.
Great just what we would need for marketing: fish oil reduces COVID symptoms...i can see the headlines now LOL.....
Why did the Board allow him to stay so long as CEO? Mind boggling. And as a CPA he didn’t eveb try to cut the salesforce. This was his expertise…cost control / right sizing the business.
We are nearing the end of 2021.....so play it out. Trying to invalidate the reduce-it patents (CVD) could take years... First generics would have to submit a filing that the patent is invalid. Next, Amarin would sue them. And Amarin is not going to sue them in Nevada LOL. The Marine case commenced in 2016 and was not decided until 2020.
The REDUCE-IT patents are valid until mid-2029 I believe or 2028 by the time the lawsuit would even be heard you would be nearing the end of the patent life.....much ado about nothing
Moreover, nobody would be stupid to pick Nevada again and a judge trial.
Agree. It was a very strong close. Will be interesting to see if it continues.
Great due diligence. Could it be that both companies are already working together behind the scenes in terms of having identified the best reps to drive CVD drug sales going forward......
the best reps in each region / coverage area
one can dream eh....
Has Dr. Alkon ever addressed it?
Having family members with Alz. A lot can happen in 6 months in terms of someone's further cognitive decline. Especially if this person is already in the moderate group.
I'm still intrigued that placebo showed improvement in the moderate group the last go around--albeit that trial was only 13 weeks.
That's funny. You must be unaware of the regulatory protection in Europe...but carry on.
You would never put that in a research note lol. The other thing is that JP Morgan could be advising on such a deal. There is supposed to be a "Chinese Wall" between research and investment banking but you would never see in a research note: PFE is looking to acquire AMRN.
Great points. I wonder what will "bridge" where we are currently trading to a potential takeout offer....
hopefully the stock starts to creep higher because do 300% or 400% premiums happen in biotech M&A.....?
maybe KM puts out a bullish forecast or some other material news occurs in the interim
Can we get some analyst upgrades....looking at you Mr. Paul Choi from Goldman lol
Can't wait. Now if Goldman will just get out of our way. I wonder if they are advising PFE. I would not be surprised.
Does Paul Choi still have his $5 price target on us. SMH
What do you think is more realistic between option 2 and option 3 or is it more likely both: option 2 and then option 3 several months or years later?
Great point. And if there is anything the FDA can do to help with the situation....I imagine Pfizer may have some pull with the FDA.....
What makes you say that? How do you know if these cafe pharma posts are real re: layoffs?
I agree the improvement in the placebo group for the most severe cohort was very bizarre. Makes you think did they get the groups mixed up or switch who was getting the drug.....SMH
Thanks for posting this. I just reviewed it. It's interesting that in the moderate group the placebo group's scores did improve as well and over time. Don't know if that indicates they got better at taking the test/assessment but 13 weeks is still a short period of time.
With Alz patients time matters. So 6 months perhaps we don't see as much of an improvement in the placebo group. Although even better would be a decline in the placebo group over 6 months and not less of a rise in their scores.
I think one we can say for certain that once Alz becomes too severe, this clearly will not work.